Active	Status	Sponsor type	Region	Phase	Filter
5 Active 3 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Yurdaydin, Cihan
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV	Active, not recruiting	3	150	Europe, US, RoW	Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda	Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.	Hepatitis Delta Virus	06/24	01/25
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease	Not yet recruiting	2	393	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline	Liver Diseases, Alcoholic	12/26	03/27
Iovino, Claudio
No trials found
Demirel, Sibel
No trials found